Skip to content

A randomized controlled trial for the fire acupuncture in the treatment of malignant pleural effusion

A randomized double-blind controlled trial for the fire acupuncture in the treatment of malignant pleural effusion

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002848
Enrollment
Unknown
Registered
2019-12-19
Start date
2020-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant pleural effusion

Interventions

Experimental group:Conventional treatment + fire acupuncture
Control group:Conventional treatment

Sponsors

Guangxi Traditional Chinese Medical University Affiliated First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. meet the above diagnostic criteria; 2. Aged 20 ~ 70 years old; 3. X-ray or b-ultrasound showed malignant pleural effusion; 4. the survival time is expected to be more than 3 months; 5. ECOG PS score =3 months; 6. no chemotherapy or intrathoracic drug injection was given within 1 month before the inclusion of treatment; 7. participate in the study voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. diagnosis of pleural effusion caused by unknown or simple hypoproteinemia; 2. routine blood tests showed that white blood cells were less than 3.5*109/L, hemoglobin was less than 80g/L, or platelets were less than 80*10^9/L; 3. severe pulmonary infection; 4. those with KPS score < 50 and estimated survival period < 3 months; 5. patients with abnormal fluid quality or multiple organ failure; 6. severe damage to the heart, liver or kidney or abnormal bone marrow function; 7. poor coagulation function, prone to massive bleeding; 8. patients with severe heart, brain, kidney and liver diseases; 9. patients cannot accept and tolerate fire needle therapy; 10. patients with mental problems who cannot cooperate.

Design outcomes

Primary

MeasureTime frame
Symptom remission rate;

Countries

China

Contacts

Public ContactWei Shi
shiwei023009@qq.com+86 13617712525

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026